Table 2 Univariate logistic regression analysis of different variables predicting pCR in the training set

Age

0.385

 ≤40 years

1

 >40 years

0.385

0.767

0.423-1.394

Menopausal status

0.518

 Pre-menopausal

1

 Post-menopausal

0.518

0.843

0.502-1.416

Tumor Size

0.029

 T1

1

 T2

0.052

0.500

0.248-1.007

 T3

0.014

0.369

0.167-0.815

 T4

0.008

0.282

0.111-0.716

Nodal status

0.432

 N0

1

 N1

0.493

0.802

0.426-1.508

 N2

0.701

1.308

0.332-5.147

 N3

0.328

1.171

0.564-5.561

Hormone receptor status

<0.001

 Negative

1

 Positive

<0.001

0.307

0.182-0.518

Regimens

<0.001

 Cyclophosphamide, epirubicin and 5-fluorouracil

1

 Cyclophosphamide, epirubicin and 5-fluorouracil followed by paclitaxel or docetaxel and epirubicin

0.158

4.779

0.544-42.018

 Navelbine and epirubicin

0.094

6.047

0.738-49.558

 Paclitaxel and carboplatin or paclitaxel and cisplatin

0.006

16.479

2.236-121.451

Cycles

0.029

 3-4

1

 1-2

0.018

0.176

0.042-0.740

 5-6

0.143

0.577

0.264-1.261